What Stanlip 145 Treats: Main Uses and Benefits

Stanlip 145 is used as an adjunctive therapy to address certain lipid imbalances in adults, focusing on managing symptoms related to systemic imbalance and helping support functional stability. Its primary indications include correcting severe hypertriglyceridemia and managing primary hypercholesterolemia or mixed dyslipidemia.

The medication is applied across domains where additional symptomatic support is needed to manage symptoms related to systemic imbalance associated with blood fat abnormalities. In cases of severe hypertriglyceridemia, Stanlip 145 helps to mitigate the risk of developing acute pancreatitis, supporting the patient during potentially acute episodes. Furthermore, it provides supportive relief that contributes to easing the overall symptom load related to complex lipid imbalances, and is utilized in clinical contexts involving individuals with Type 2 Diabetes.

---

“This medication supports the patient during difficult episodes by easing distress associated with lipid fluctuations.”

---

Quick Fact: Relief for Systemic Imbalance

Property	Description
Primary Indication	Severe Hypertriglyceridemia
Key Symptom Domain	Abnormally High Blood Fats (Triglycerides, VLDL-C)
Patient Benefit	Supports maintenance of systemic stability
Clinical Context	Adjunct to diet and exercise

Regulatory References

1. DailyMed Label for Fenofibrate

Who Can and Cannot Use Stanlip 145?

Eligibility for Stanlip 145, which contains Fenofibrate, is determined by clear restrictions and contraindications defined in official regulatory labeling. Use is primarily established for adult patients requiring treatment for specific lipid disorders.

Populations For Whom Use is Contraindicated

Stanlip 145 is formally contraindicated and must not be used in several patient groups, including:

• Patients with severe renal impairment (typically eGFR < 30 mL/min/1.73 m^2) or those on dialysis.
• Patients with active liver disease, including biliary cirrhosis or unexplained persistent liver function abnormalities.
• Patients with pre-existing gallbladder disease.
• Nursing mothers (breastfeeding women).
• Patients with a known hypersensitivity to fenofibrate or related fibrates.

Restricted and Non-Established Use

Population Category	Regulatory Status
Pediatric Population (under 18 years)	Not recommended; safety and efficacy are not established.
Moderate Renal Impairment (eGFR 30–59)	Use is conditional; a dose reduction is required due to altered drug clearance.
Pregnancy	Use is restricted; recommended only if the potential benefit outweighs the potential risk to the fetus.
Geriatric Patients	Use requires caution and is dependent upon an assessment of renal function.

These eligibility rules strictly classify who can and cannot use the medicine under labeled conditions based on age, organ function, reproductive status, and pre-existing co-morbidities.

Interactions with other medicines and products

Stanlip 145 (Fenofibrate) has officially documented interaction patterns that affect the exposure to the drug or potentiate pharmacodynamic effects when co-administered with certain substances, as established in regulatory labeling.

Documented Interaction Patterns

Category	Official Interaction Outcome	Constraint / Rule
Coumarin Anticoagulants (e.g., Warfarin)	Fenofibrate officially enhances the anticoagulant effect (pharmacodynamic potentiation).	Requires close monitoring of coagulation status (PT/INR) at the start of co-administration.
HMG-CoA Reductase Inhibitors (Statins)	Officially documented increased risk of myopathy and rhabdomyolysis.	Risk is noted to be higher in the elderly, and patients with diabetes or renal failure.
Bile-Acid Binding Resins (e.g., Cholestyramine)	Resins impede fenofibrate absorption, resulting in reduced systemic exposure.	Fenofibrate must be administered at least 1 hour before or 4 to 6 hours after the resin.
Immunosuppressants (e.g., Cyclosporine)	Associated with risk of reversible renal function deterioration, potentially affecting drug clearance.	Requires consideration for accumulation of the active metabolite, fenofibric acid.

Fenofibrate also has a documented drug–food interaction: its absorption is officially improved when taken with food, as it is less well absorbed from an empty stomach. No substances are formally classified as strictly contraindicated in the major interaction sections of the official prescribing information. These interaction rules structure how the medicine may be used with other regulated products.

Targeting the PPAR alpha Receptor

Stanlip 145 works by acting as an agonist (activator) of the Peroxisome Proliferator-Activated Receptor alpha (PPAR alpha), a key nuclear receptor that controls the activity of genes involved in fat and lipoprotein metabolism, particularly in the liver. This activation influences gene transcription related to lipid processing, leading to subsequent physiological consequences.

---

Enhancing Triglyceride Breakdown

The activation of PPAR alpha increases the catabolism of triglyceride-rich particles (like VLDL) in the circulation. It does this by boosting the activity of the enzyme lipoprotein lipase (LPL) and simultaneously reducing the production of Apolipoprotein C-III, a protein that normally inhibits LPL. This combined action results in a reduction in circulating triglycerides.

---

Modulating HDL Component Synthesis

A secondary action involves stimulating the synthesis of Apolipoprotein A-I and Apo A-II, which serve as structural components of High-Density Lipoprotein (HDL). The resulting increase in these components contributes to an increase in circulating HDL-C levels and is part of the mechanism that facilitates reverse cholesterol transport.

How to Use Stanlip 145: Administration Guidelines

Stanlip 145 (micronised fenofibrate) is a prescription-only medication. The medication functions as an adjunct to a proper lipid-lowering diet and non-pharmacological therapies such as exercise, which are continued throughout treatment.

---

Dosing and Schedule

Indication	Standard Adult Dose	Frequency	Maximum Daily Dose
Primary Hypercholesterolemia or Mixed Dyslipidemia	145 mg	Once daily	145 mg
Severe Hypertriglyceridemia	Initial dose: 48 mg or 145 mg	Once daily	145 mg

---

Administration Instructions

The route of administration is oral. The tablet is taken once daily and may be administered with or without food. It is important that the tablet be swallowed whole; patients must not crush, break, dissolve, or chew the film-coated tablet.

For patients taking a bile acid binding resin (another lipid-lowering agent), Stanlip 145 is taken at least 1 hour before or 4 to 6 hours after the resin to prevent its absorption from being significantly reduced.

---

Population-Specific Use and Monitoring

The dosage is adjusted for patients with reduced kidney function. For individuals with mild-to-moderate renal impairment, the dose is typically started at the lower strength (e.g., 48 mg once daily), with subsequent dose increases based on evaluation of both the lipid response and renal function. The safety and effectiveness of Stanlip 145 have not been established in children under the age of 18. Treatment efficacy is monitored periodically, and therapy is typically discontinued if an adequate response is not achieved after two months of treatment at the maximum recommended dose.

Research Evidence / Overview of Studies for Stanlip 145

Evidence for Managing Severe Hypertriglyceridemia

Research explored Stanlip 145 within the context of patients diagnosed with severe hypertriglyceridemia, a condition characterized by high levels of triglycerides in the blood (typically 500 mg/dL or higher). The study design was primarily randomized, double-blind, placebo-controlled clinical trials (RCTs).

Studies reported measurements during the study period, describing patterns of change in the measured triglyceride biomarker levels in the observed populations. These findings describe group patterns related to how blood fats changed in the context of the research.

Dedicated trials have not conclusively established the association of this therapy with a reduced incidence of acute pancreatitis. Furthermore, data are still emerging regarding the sustained long-term outcomes, as follow-up durations were limited in the primary response studies.

---

Evidence for Primary Hypercholesterolemia and Mixed Dyslipidemia

For patients diagnosed with high cholesterol or a combination of lipid imbalances (mixed dyslipidemia), the evidence base includes large-scale, long-term RCTs, such as the FIELD and ACCORD Lipid trials. These studies explored outcomes related to major cardiovascular events (like heart attack or death from heart disease), alongside changes in key lipid biomarkers like LDL-C and HDL-C.

Regarding the primary outcome axis of major events, research describes that the largest trials, which monitored responses over several years, reported that the overall goal of reducing the primary composite endpoint of heart disease events did not achieve statistical significance in the total study population.

Subgroup findings are uncertain, as studies observing responses over defined time intervals suggest that patterns of change in macrovascular outcomes were only described in specific, high-risk groups of patients. The independent association of Stanlip 145 with heart outcomes is difficult to establish because many participants in the long-term trials were also receiving statins.

---

Research Focus Beyond Lipid Levels: Type 2 Diabetes

Research explored Stanlip 145 within the context of patients with Type 2 Diabetes Mellitus. Long-term RCTs examined whether the medicine was associated with changes in the progression of certain diabetes-related complications.

The studies monitored changes in diabetic retinopathy (eye disease), specifically the need for laser treatment, and monitored changes in markers linked to diabetic kidney changes (albuminuria). Studies reported measurements during the study period, describing patterns observed in the progression of retinopathy and the occurrence of albuminuria compared to a placebo.

It is important to note that the findings for microvascular outcomes are largely derived from secondary analyses, meaning they were not the main, primary focus of the large-scale trials.

Key Studies & References Fenofibrate official prescribing information (Example Label for FENOFIBRATE tablet)

Common questions about Stanlip 145 (FAQ)

---

Q: How quickly can a person expect Stanlip 145 to start working?

Official prescribing information indicates that the therapeutic effects of Stanlip 145 are monitored by measuring lipid levels in the blood. These measurements are typically checked by a healthcare provider at intervals of four to eight weeks after beginning treatment. This monitoring determines if the medicine is providing the desired lipid response.

---

Q: Is Stanlip 145 the same as the generic version?

Stanlip 145 contains the active ingredient fenofibrate, but it is a specific, modern formulation known as micronized or nanoparticulated fenofibrate. This specialized particle size is designed to improve the drug's absorption, or bioavailability. Because of this specific formulation, official sources indicate that Stanlip 145 is not necessarily considered interchangeable with all other generic fenofibrate products on a milligram-to-milligram basis.

---

Q: Does Stanlip 145 interact with blood pressure medication?

Official information describes that fenofibrate may affect the way some blood pressure medicines work. For instance, it can increase the concentration of certain medicines like losartan (an Angiotensin Receptor Blocker) in the blood. The co-administration of these medicines is usually managed through close monitoring and potential dose adjustments.

---

Q: What happens if a person occasionally misses a dose of Stanlip 145?

Official drug information suggests that if a dose is missed, taking it as soon as it is remembered is the general recommendation. However, if it is nearly time for the next scheduled dose, skipping the missed one entirely is typically advised. It is important never to take a double dose to make up for a missed one.

---

Q: Is Stanlip 145 safe to use long-term?

The official product information does not specify a maximum duration for treatment. For patients who show an inadequate response, the therapy is typically discontinued after two months at the maximum recommended dose. For those who respond well, the medicine is often continued long-term under regular medical supervision to maintain the lipid-lowering effect.

---

Q: Will Stanlip 145 cure high cholesterol permanently?

Official documents describe Stanlip 145 as being used as an adjunct to a proper diet and exercise plan. It works to manage and decrease fatty substances in the blood only for as long as a person continues to take the medicine. Therefore, high cholesterol is managed and treated but is not permanently cured by Stanlip 145.

---

Q: Is Stanlip 145 known to cause weight gain?

Weight gain has been reported in postmarketing surveillance as an adverse reaction; however, the official incidence is not specified. It is important to note that weight gain is not listed among the more common side effects documented in clinical trials for this medicine.

---

Q: Are there any non-prescription supplements that interact with Stanlip 145?

The use of Stanlip 145 alongside supplements like fish oil (omega-3 fatty acids) has been explored, and no direct drug interaction has been identified. The official context suggests that concurrent use requires caution. Because both fenofibrate and omega-3s can affect liver enzyme levels, the co-administration is associated with the need for liver function monitoring.

---

Q: Can Stanlip 145 be taken at any time of day?

Official administration guidelines state that Stanlip 145 should be taken once daily at around the same time each day to help maintain consistent levels in the body. The choice of taking it in the morning or evening is generally determined by the prescribing healthcare provider.

---

Q: Is it normal to feel tired when first starting Stanlip 145?

Unusual tiredness or general weakness is listed in official reports as a rare side effect, meaning its frequency is low or not precisely known. Regulatory information notes that tiredness or muscle weakness can also be symptoms associated with serious, though rare, muscle conditions like rhabdomyolysis.

---

Q: How long after stopping Stanlip 145 do the effects wear off?

According to official pharmacokinetic data, the active component of fenofibrate has an elimination half-life of approximately 20 hours in the body. This indicates that once the medicine is discontinued, its lipid-lowering effects will gradually diminish as the drug is slowly cleared from the system.

---

Q: Can a person take Stanlip 145 with aspirin?

Official documentation indicates that no direct chemical interaction has been found between fenofibrate (the active ingredient in Stanlip 145) and aspirin. While no direct interaction has been found, combining any medications requires guidance from a healthcare professional.

---

Q: Are there any documented interactions between Stanlip 145 and alcohol?

Official warnings indicate that while there is no direct chemical interaction, heavy or excessive alcohol use should be limited during treatment. High alcohol intake can raise triglyceride levels, potentially reducing the medicine's effectiveness. Alcohol consumption can also increase the risk of serious side effects associated with fenofibrate, specifically liver damage and pancreatitis.

How to Store and Dispose of Stanlip 145 (Fenofibrate)

Stanlip 145 tablets must be stored according to specific conditions mandated by regulatory labeling to ensure the stability of the micronized fenofibrate.

---

Storage Requirements

The medication must be stored at Controlled Room Temperature, which is between 20°C and 25°C (68°F and 77°F). It is required to keep the tablets protected from moisture and excessive heat.

---

Container and Safety

Stanlip 145 should be kept in the container it came in, ensuring it remains tightly closed and light-resistant. As with all medications, it must be stored out of the reach of children.

---

Disposal Instructions

Unused or expired Stanlip 145 tablets must be disposed of according to local regulations. Medicine should not be flushed down the toilet or poured into a drain unless specific instructions permit it.